315 related articles for article (PubMed ID: 16794200)
21. Low-dose enteric-coated aspirin as an antiplatelet preparation.
McLeod LJ; Roberts MS; Seville PR
Med J Aust; 1988 Feb; 148(4):207. PubMed ID: 3340049
[No Abstract] [Full Text] [Related]
22. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
[TBL] [Abstract][Full Text] [Related]
24. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
[TBL] [Abstract][Full Text] [Related]
25. Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin.
Scavone M; Rizzo J; Femia EA; Podda GM; Bossi E; Caberlon S; Paroni R; Cattaneo M
Thromb Haemost; 2020 Oct; 120(10):1442-1453. PubMed ID: 32717754
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of acetylsalicylic acid in comparison with an oral solution after single-dose administration to healthy volunteers: a phase I, two-way crossover study.
Loprete L; Leuratti C; Scarsi C; Radicioni M
Clin Drug Investig; 2014 Jan; 34(1):19-25. PubMed ID: 24132773
[TBL] [Abstract][Full Text] [Related]
27. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
[TBL] [Abstract][Full Text] [Related]
28. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers.
Karha J; Rajagopal V; Kottke-Marchant K; Bhatt DL
Am Heart J; 2006 May; 151(5):976.e7-11. PubMed ID: 16644316
[TBL] [Abstract][Full Text] [Related]
29. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution.
Feldman M; Cryer B
Am J Cardiol; 1999 Aug; 84(4):404-9. PubMed ID: 10468077
[TBL] [Abstract][Full Text] [Related]
30. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
31. Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan).
Serebruany VL; Malinin AI; Hanley DF
Thromb Haemost; 2008 Jan; 99(1):116-20. PubMed ID: 18217142
[TBL] [Abstract][Full Text] [Related]
32. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
33. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations.
Schwertner HA; McGlasson D; Christopher M; Bush AC
Thromb Res; 2006; 118(4):529-34. PubMed ID: 16298420
[TBL] [Abstract][Full Text] [Related]
34. Dipyridamole bioavailability in subjects with reduced gastric acidity.
Derendorf H; VanderMaelen CP; Brickl RS; MacGregor TR; Eisert W
J Clin Pharmacol; 2005 Jul; 45(7):845-50. PubMed ID: 15951475
[TBL] [Abstract][Full Text] [Related]
35. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
37. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B
Gurbel PA; Bliden KP; Tantry US
J Thromb Thrombolysis; 2021 Feb; 51(2):260-264. PubMed ID: 33170486
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone.
Antonino MJ; Coppolecchia R; Mahla E; Bliden KP; Tantry US; Gurbel PA
Thromb Res; 2010 Nov; 126(5):384-5. PubMed ID: 19446864
[TBL] [Abstract][Full Text] [Related]
39. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery.
Vanags D; Rodgers SE; Lloyd JV; Bochner F
Thromb Res; 1990 Sep; 59(6):995-1005. PubMed ID: 2264023
[TBL] [Abstract][Full Text] [Related]
40. Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers.
Caplain H
Cerebrovasc Dis; 2005; 19(4):214-9. PubMed ID: 15703464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
